| 1 |
Struzik J, Szulc-Dabrowska L. NF-κB signaling in targeting tumor cells by oncolytic viruses—therapeutic perspectives [J]. Cancers, 2018, 10(11): E426.
|
| 2 |
Cui Z H, Xuan Y Z. Advances in the relationship between Nuclear factor-κB signal transduction pathway and tumor[J]. World Latest Medicne Information , 2015(21): 56-58.
|
| 3 |
Shujun Y, Jian L, Yu C, et al. MicroRNA-216a promotes M1 macrophages polarization and atherosclerosis progression by activating telomerase, via, the Smad3/NF-κB pathway[J]. Biochim Biophys Acta Mol Basis Dis, 2018, pii: S0925-4439(18)30220-30225.
|
| 4 |
李国仁，于世忠. 中国继发性食管癌的现状和进展[J]. 中华胸部外科电子杂志，2018, 5(1): 53-58.
|
| 5 |
Zhang Q, Lenardo M J, Baltimore D. 30 years of NF-κB: A blossoming of relevance to human pathobiology[J]. Cell, 2017, 168(1-2): 37-57.
|
| 6 |
Lehman H L, Kidacki M, Warrick J I, et al. NF-κB hyperactivation causes invasion of esophageal squamous cell carcinoma with EGFR overexpression and p120-catenin down-regulation [J]. Oncotarget, 2018, 9(13): 11180-11196.
|
| 7 |
Chen Z J. Ubiquitin signalling in the NF-κB pathway[J]．Nat Cell Biol，2005，7(8): 758-765.
|
| 8 |
Taniguchi K, Yamachika S, He F, et al. p62/SQSTM1-Dr. Jekyll and Mr. Hyde that prevents oxidative stress but promotes liver cancer[J]. Febs Letters, 2016, 590(15): 2375-2397.
|
| 9 |
Sun S C. The non-canonical NF-κB pathway in immunity and inflammation[J]. Nat Rev Immunol, 2017, 17(9): 545-558.
|
| 10 |
Slotta C, Schlüter T, Ruizperera L M, et al. CRISPR/Cas9-mediated knockout of c-REL in HeLa cells results in profound defects of the cell cycle[J]. PLoS One, 2017, 12(8): e0182373.
|
| 11 |
Khan A, Fornes O, Stigliani A, et al. JASPAR 2018: update of the open-access database of transcription factor binding profiles and its web framework[J]. Nucleic Acids Res, 2017, 46(D1): D260-D266.
|
| 12 |
Bradford J W, Baldwin A S. IKK/nuclear factor-kappa B and oncogenesis: Roles in tumor-initiating cells and in the tumor microenvironment[J]. Adv Cancer Res, 2014，121: 125-145.
|
| 13 |
Taniguchi K, Karin M. NF-κB, inflammation, immunity and cancer: coming of age[J]. Nat Rev Immunol, 2018, 22(2): 1-16.
|
| 14 |
Siegel R L, Miller K D, Jemal A. Cancer statistics, 2018[J]. CA-Cancer J Clin, 2017, 67(1): 7-30.
|
| 15 |
Blakely C M, Pazarentzos E, Olivas V, et al. NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer[J]. Cell rep, 2015, 11(1): 98-110.
|
| 16 |
Yang L, Zhou Y, Li Y，et al.Mutations of p53 and KRAS activate NF-κB to promote chemo resistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells[J]. Cancer Lett, 2015，357(2): 520-526.
|
| 17 |
王佳丽，张翔宇，邓佳，等. Bin1基因通过NF-κB途径抑制非小细胞肺癌A549细胞的迁移和侵袭能力[J]. 中国肿瘤生物治疗杂志，2016, 23(4): 481-485.
|
| 18 |
Yodkeeree S, Pompimon W, Limtrakul P．Crebanine，an aporphine alkaloid, sensitizes TNF-αinduced apoptosis and suppressed invasion of human lung adenocarcinoma cells A549 by blocking NF-κB regulated gene products[J]. Tumour Biol，2014，35(9): 8615-8624.
|
| 19 |
Gao P, Gao Y J, Liang H L．Effect of NF-κB inhibitor PDTC on VEGF and endostatin expression of mice with Lewis lung cancer[J]. Asian Pac J Trop Med，2015, 8(3): 220-224.
|
| 20 |
Zeng Q, Li S, Zhou Y，et al.Interleukin-32 contributes to invasion and metastasis of primary lung adenocarcinoma via NF-kappaB induced matrix metalloproteinases 2 and 9 expression[J]．Cytokine，2014，65(1): 24-32.
|
| 21 |
Cheng X, Gu J, Zhang M，et al. Astragaloside Ⅳ inhibits migration and invasion in human lung cancer A549 cells via regulating PKC-α-ERK1/2-NF-κB pathway[J]. Int Immunopharmacol，2014，23(1): 304-313.
|
| 22 |
Kumar M, Allison D F, Baranova N N，et al.NF-κB regulates mesenchymal transition for the induction of non-small cell lung cancer initiating cells[J]．PLoS One，2013，8(7): e68597.
|
| 23 |
Slotta C, Storm J, Pfisterer N, et al. IKK1/2 protect human cells from TNF-mediated RIPK1-dependent apoptosis in an NF-κB-independent manner[J]. Biochim Biophys, 2018, 1865(8): 1025-1033.
|
| 24 |
Xia Y, Shen S, Verma I M. NF-κB, an active player in human cancers[J]. Cancer Immunol Res, 2014, 2(9): 823-830.
|
| 25 |
Xiao Z, Jiang Q, Willette-Brown J, et al. The pivotal role of IKKα in the development of spontaneous lung squamous cell carcinomas[J]. Cancer Cell, 2013, 23(4): 527-540.
|
| 26 |
Li N, Wu X, Holzer R G, et al. Loss of acinar cell IKKα triggers spontaneous pancreatitis in mice[J]. J Clin Investig, 2013, 123(5): 2231-2243.
|
| 27 |
Martin B N, Wang C, Willette-Brown J, et al. IKKα negatively regulates ASC-dependent inflammasome activation[J]. Nat Commun, 2014, 5(5): 4977.
|
| 28 |
Xiao D, Jia J, Shi Y, et al. Opposed expression of IKKα：Loss in keratinizing carcinomas and gain in non-keratinizing carcinomas[J]. Oncotarget, 2015, 6(28): 25499-25505.
|
| 29 |
Song N Y, Zhu F, Wang Z, et al. IKKα inactivation promotes Kras-initiated lung adenocarcinoma development through disrupting major redox regulatory pathways[J]. Proc Natl Acad Sci, 2018, 115(4): E812-E821.
|
| 30 |
Grinberg-Bleyer Y, Oh H, Desrichard A, et al. NF-κB c-Rel is crucial for the regulatory T cell immune checkpoint in cancer[J]. Cell, 2017, 170(6): 1096-1108.
|
| 31 |
Lin C, Song L, Gong H，et al. Nkx2-8 down regulation promotes angiogenesis and activates NF-kappaB in esophageal cancer[J]. Cancer Res，2013，73(12): 3638-3648.
|
| 32 |
刘亮，贺红梅，左静，等. 食管上皮癌变过程中NF-κB与hTERT的表达及其意义[J]. 肿瘤防治研究，2014, 41(12): 1304-1306.
|
| 33 |
Cai Q Y, Liang G Y, Zheng Y F, et al. CCR7 enhances the angiogenic capacity of esophageal squamous carcinoma cells in vitro via activation of the NF-κB/VEGF signaling pathway[J]. Am J Transl Res, 2017, 9(7): 3282-3292.
|
| 34 |
Huang C Y, Lee C H, Tu C C, et al. Glucose-regulated protein 94 mediates progression and metastasis of esophageal squamous cell carcinoma via mitochondrial function and the NF-kB/COX-2/VEGF axis[J]. Oncotarget, 2018, 9(10): 9425-9441.
|
| 35 |
Ming X Y, Zhang X, Cao T T, et al. RHCG Suppresses Tumorigenicity and Metastasis in Esophageal Squamous Cell Carcinoma via Inhibiting NF-κB Signaling and MMP1 Expression[J]. Theranostics, 2018, 8(1): 185-198.
|
| 36 |
Mohammed S, Harikumar K B. Role of Nutraceuticals in Cancer Chemosensitization[M]//Bharti A C, Bhushan B．Cancer sensitizing agents for chemotherapy, 2018, 61-76.
|
| 37 |
Dimitrakopoulos F D, Antonacopoulou A G, Kottorou A E, et al. NF-κB2 genetic variations are significantly associated with non-small cell lung cancer risk and overall survival[J]. Sci Rep-UK, 2018, 8(1): 5259-5270.
|
| 38 |
Zhao Y, Foster N R, Meyers J P, et al. A phase Ⅰ/Ⅱ study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell Lung cancer: North central cancer treatment group (NCCTG)-N0321[J]. J Thorac Oncol, 2015, 10(1): 172-180.
|
| 39 |
Kontopodis E, Kotsakis A, Kentepozidis N, et al. A phase Ⅱ，open-label trial of bortezomib (VELCADE®) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer[J]. Cancer chemoth pharm, 2016, 77(5): 940-956.
|
| 40 |
Qu Y Q, Gordillo-Martinez F, Law B Y K, et al. 2-aminoethoxydiphenylborane sensitizes anti-tumor effect of bortezomib via suppression of calcium-mediated autophagy[J]. Cell Death Dis, 2018, 9(3): 361-380.
|
| 41 |
Lu G, Middleton R E, Sun H, et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins[J]. Science, 2014, 343(6168): 305-309.
|
| 42 |
Würth R, Thellung S, Bajetto A, et al. Drug-repositioning opportunities for cancer therapy: novel molecular targets for known compounds[J]. Drug Discov Today, 2016, 21(1): 190-199.
|
| 43 |
König H G, Watters O, Kinsella S, et al. A constitutively-active IKK-complex at the axon initial segment[J]. Brain res, 2018, 1678: 356-366.
|
| 44 |
Lee K E, Hahm E, Bae S, et al. The enhanced tumor inhibitory effects of gefitinib and Lascorbic acid combination therapy in nonsmall cell lung cancer cells[J]. Oncol lett, 2017, 14(1): 276-282.
|
| 45 |
Tang H, Shrager J B. CRISPR/Cas-mediated genome editing to treat EGFR-mutant lung cancer: a personalized molecular surgical therapy[J]. EMBO mol med, 2016, 8(2): 83-85.
|
| 46 |
Liu P, Wang Z, Brown S, et al. Liposome encapsulated Disulfiram inhibits NFκB pathway and targets breast cancer stem cells in vitro and in vivo[J]. Oncotarget, 2014, 5(17): 7471-7485.
|
| 47 |
Jivan R, Peres J, Damelin L H, et al. Disulfiram with or without metformin inhibits oesophageal squamous cell carcinoma in vivo[J]. Cancer lett, 2018, 417: 1-10.
|